Senti Biosciences Files 8-K

Ticker: SNTI · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1854270

Sentiment: neutral

Topics: corporate-filing, 8-K, financial-reporting

TL;DR

Senti Bio filed an 8-K on Dec 3rd. Standard corporate update.

AI Summary

Senti Biosciences, Inc. filed an 8-K on December 3, 2024, reporting other events and financial statements. The company, formerly known as Dynamics Special Purpose Corp., is incorporated in Delaware and based in South San Francisco, California.

Why It Matters

This filing provides an update on Senti Biosciences' corporate activities and financial reporting, which is important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no immediate material financial or operational changes indicated.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Senti Biosciences, Inc.?

The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 3, 2024.

When was Senti Biosciences, Inc. previously known by another name?

Senti Biosciences, Inc. was formerly known as Dynamics Special Purpose Corp. until March 31, 2021, and also as Senti Biosciences, Inc. until June 15, 2022.

Where are Senti Biosciences, Inc.'s principal executive offices located?

The principal executive offices are located at 2 Corporate Drive, First Floor, South San Francisco, California, 94080.

What is the SIC code for Senti Biosciences, Inc.?

The Standard Industrial Classification (SIC) code for Senti Biosciences, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

What is the fiscal year end for Senti Biosciences, Inc.?

The fiscal year end for Senti Biosciences, Inc. is December 31.

Filing Stats: 786 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-12-03 16:02:26

Key Financial Figures

Filing Documents

01

Item 8.01. Other Events. Senti Biosciences, Inc. (the "Company") has made available a slide presentation deck relating to initial clinical data from the Phase 1 clinical trial of SENTI-202, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expectation about any or all of the following: timing of its clinical trials for SENTI-202; the timing of availability of data from the ongoing Phase 1 clinical trial of SENTI-202; as well as the ability of any product candidate to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data. Forward-looking statements can be identified by terms such as "will," "intent," "expect," "plan," "potential," "would" or similar expressions and the negative of those terms. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Although the Company believes that such statements are based on reasonable assumptions, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company's control, you should not rely on these forward-looking statements as predictions of future events. These risks and uncert

forward-looking statements contained in this Current Report on Form 8-K, other than to the extent required by law

forward-looking statements contained in this Current Report on Form 8-K, other than to the extent required by law.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Presentation Slide Deck 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Senti Biosciences, Inc. Date: December 3, 2024 By: /s/ Timothy Lu, M.D., Ph.D. Timothy Lu, M.D., Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing